Abstract
Tankyrases are poly(ADP-ribose) polymerases that have many cellular functions. They play pharmaceutically important roles, at least in telomere homeostasis and Wnt signaling, by covalently ADP-ribosylating target proteins and consequently regulating their functions. These features make tankyrases potential targets for treatment of cancer. We report here crystal structures of human tankyrase 2 catalytic fragment in complex with a byproduct, nicotinamide, and with selective inhibitors of tankyrases (IWR-1) and PARPs 1 and 2 (olaparib). Binding of these inhibitors to tankyrase 2 induces specific conformational changes. The crystal structures explain the selectivity of the inhibitors, reveal the flexibility of a substrate binding loop, and explain existing structure-activity relationship data. The first crystal structure of a PARP enzyme in complex with a potent inhibitor, IWR-1, that does not bind to the widely utilized nicotinamide-binding site makes the structure valuable for development of PARP inhibitors in general.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1360-1367 |
| Number of pages | 8 |
| Journal | Journal of medicinal chemistry |
| Volume | 55 |
| Issue number | 3 |
| DOIs | |
| State | Published - Feb 9 2012 |
| Externally published | Yes |
ASJC Scopus subject areas
- Molecular Medicine
- Drug Discovery